Cardiovascular Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
ATS Medical, Inc.
Global deal signed for surgical cryotherapy treatment for atrial fibrillation
December 7th, 2004
ATS Medical, Inc., (ATSI) announced that it has entered into a global partnership agreement with Canadian-based CryoCath Technologies, Inc., to market CryoCath's surgical cryotherapy products for the ablation of cardiac arrhythmias. Under terms of the agreement, ATS has been granted co-promotion rights in the U.S. as well as exclusive distribution rights in the rest of the world including Europe and Asia. The transaction allows CryoCath to continue their quest to be a dominant player in the atrial fibrillation (AF) market. According to Michael D. Dale, ATS Medical president and CEO, "The use of ablation therapy for the treatment of AF and, more...
Source: Cardiovascular Business Week (2004-12-07)
|
